Fludarabine mono — Competitive Intelligence Brief

Fludarabine mono (Fludarabine mono) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Purine analog antimetabolite. Area: Oncology.

phase 3 Purine analog antimetabolite Ribonucleotide reductase; DNA polymerase Oncology Small molecule

Target snapshot

Fludarabine mono (Fludarabine mono) — German CLL Study Group. Fludarabine is a purine analog that inhibits DNA synthesis by blocking ribonucleotide reductase and incorporating into DNA, leading to cell death in rapidly dividing lymphocytes.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fludarabine mono TARGET	Fludarabine mono	German CLL Study Group	phase 3	Purine analog antimetabolite	Ribonucleotide reductase; DNA polymerase
Gemcitabine (GEM)	Gemcitabine (GEM)	Sun Yat-sen University	marketed	Nucleoside analog; antimetabolite	Ribonucleotide reductase; DNA polymerase
Chemotherapy,Gemcitabine based regimen	Chemotherapy,Gemcitabine based regimen	Eye & ENT Hospital of Fudan University	phase 3	Nucleoside analog; antimetabolite chemotherapy	Ribonucleotide reductase; DNA polymerase
Chemotherapy, gemcitabine	Chemotherapy, gemcitabine	University of Erlangen-Nürnberg Medical School	phase 3	Nucleoside analog; antimetabolite chemotherapy	Ribonucleotide reductase; DNA polymerase
Gemcitabine alone	Gemcitabine alone	Intergroupe Francophone de Cancerologie Thoracique	phase 3	Nucleoside analog antimetabolite	Ribonucleotide reductase; DNA polymerase
clofarabine, fludarabine and busulfan, CloFluBu	clofarabine, fludarabine and busulfan, CloFluBu	Vastra Gotaland Region	phase 3	Chemotherapy combination (nucleoside analogs + alkylating agent)	DNA synthesis and repair pathways; ribonucleotide reductase; DNA polymerase
Fludarabine (Bayer)	Fludarabine (Bayer)	Chinese PLA General Hospital	marketed	Purine analog antimetabolite	Ribonucleotide reductase, DNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Purine analog antimetabolite class)

1. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 1 drug in this class
2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
3. Chinese PLA General Hospital · 1 drug in this class
4. French Innovative Leukemia Organisation · 1 drug in this class
5. German CLL Study Group · 1 drug in this class
6. National Cancer Institute (NCI) · 1 drug in this class
7. South China Children's Leukemia Group · 1 drug in this class
8. Technische Universität Dresden · 1 drug in this class
9. University of California, San Francisco · 1 drug in this class